Background: Pheochromocytomas and paragangliomas are intra-and extra-adrenal neoplasms
Introduction
Paragangliomas are tumors of sympathetic and parasympathetic paraganglia cells. Pheochromocytomas are a specifi c type of paraganglioma that originate in the adrenal medulla. According to the 2004 World Health Organization defi nition, a pheochromocytoma is an endocrine tumor that originates in catecholamine-producing chromaffi n cells of the adrenal medulla. Paragangliomas can arise in many different parts of the body, but they are classifi ed by anatomic location into intra-adrenal and extra-adrenal sites. Extra-adrenal paragangliomas are further classifi ed into four subgroups: branchiomeric, intravagal, aorticosympathetic, and visceral-autonomic. 1 This is an important distinction because the majority of head and neck paragangliomas are of parasympathetic origin and do not secrete catecholamines. Catecholamine status has important implications for the management and treatment of these tumors.
Historically, the treatment of malignant pheochromocytoma has been challenging. There is no cure, so treatment currently focuses on alleviating symptoms. Traditional anticancer treatments have been mostly ineffective, and studying outcomes of new forms of treatment has been diffi cult because the low prevalence of malignant disease makes it diffi cult to assemble adequately sized study cohorts. Further complicating this is a lack of consensus on how to distinguish benign from malignant pheochromocytoma, as well as a lack of understanding on how these tumors develop. However, recent fi ndings have advanced our understanding of the genetic and molecular causes of pheochromocytoma, which is leading to the development of new therapies. Standard therapies for malignant pheochromocytoma are mostly nonspecifi c therapies that indiscriminately target dividing cells. The newer therapies being developed are targeted therapies based on the molecular mechanisms involved in the formation of malignant pheochromocytoma. This is a change in our thinking and our approach to these cancers, which has been possible only since the molecular mechanisms of formation of malignant pheochromocytoma have come to be understood. This article reviews the changing paradigms in the treatment of malignant pheochromocytoma based on this new molecular and genetic evidence. The focus is on tumors of sympathetic origin.
Malignant Pheochromocytoma
Unlike most tumors, no molecular or cellular markers identify a pheochromocytoma as malignant. Vascular invasion, cellular atypia, and even local recurrence do not defi nitively identify a pheochromocytoma as malignant. Currently, a malignant pheochromocytoma is defi ned only by the presence of metastasis. 2 The World Health Organization tumor classifi cation suggests that between 3% and 13% of all pheochromocytomas are malignant. 2 Researchers from the Mayo Clinic found that pheochromocytomas occur in roughly 10 per 1,000,000 people. 3 In the United States in 2002, the incidence of malignant pheochromocytoma was 93 cases in 400 million people. 4 These statistics correspond with the World Health Organization's data and suggest that in the United States, approximately 10% of all pheochromocytomas are malignant. When considering both intra-and extraadrenal paragangliomas, the malignancy rate increases from 13% to 36%. 5 Extra-adrenal paragangliomas are more commonly malignant than intra-adrenal paragangliomas. The wider range of malignancy rates reported in the literature may also be the result of a nonstandardized defi nition of malignancy has been used in the past. The 5-year survival rate for malignant disease is estimated to be between 34% and 60%, depending on the location of metastasis. Patients with bone metastasis survive the longest, and those with lung and liver metastasis have the shortest life expectancies. 5 Surgery is the main treatment for both benign and malignant pheochromocytoma. For malignant disease, a regimen of resection and debulking is recommended to reduce the tumor burden and symptoms of catecholamine excess, but recurrence rates are high. Treatment with iodine-131-meta-iodobenzylguanidine (I 131 -MIBG) is the most successful adjunct to surgical treatment and has shown some ability to cure in a small number of patients. Systemic chemotherapy is the second most useful adjunct, but its effects are mostly limited to short-term symptomatic relief, with recurrence rates of almost 100%. External beam radiation is used for treatment of head and neck paragangliomas of parasympathetic origin. It has been largely ineffective in treating metastatic pheochromocytomas or paragangliomas of sympathetic origin. For these tumors, external beam radiation is most benefi cial for the treatment of metastasis to the bone. Experience with radiofrequency ablation for these cancers is minimal.
Genetics of Pheochromocytoma
Most pheochromocytomas are sporadic tumors, but roughly 24% develop from hereditary germline mutations. 6 Mutations of six different genes are known to cause hereditary pheochromocytomas and paragangliomas: the von Hippel-Lindau gene (VHL), the RET proto-oncogene, the neurofi bromatosis type 1 gene (NF1), the succinate dehydrogenase B subunit gene (SDHB), the succinate dehydrogenase D subunit gene (SDHD), and the KIF1BBeta gene (Table 1) . [6] [7] [8] [9] [10] [11] Recent evidence has shown that these mutations are part of two distinct molecular pathways. Mutations of VHL, SDHB, and SDHD cause errors in the HIF hypoxia-driven transcription pathway ( Figure) , and mutations of RET and NF1 cause errors in RNA synthesis and metabolism through the MAPK pathway. KIF1BBeta is a more recently discovered mutation. Its pathway is not completely elucidated but seems to be connected to both the HIF and MAPK pathway. 12 Gene expression profi les from tumors with these mutations show a predictable gene expression signature that can reliably predict the type of mutation causing the tumor formation.
HIF is a transcription factor responsible for regulating the cellular response to hypoxia. HIF is constitutively expressed and regulated by the oxygen tension in a cell. Under normoxic conditions, an ubiquitination process that is dependent on VHL continually degrades the HIF protein. 13 Under hypoxic conditions, HIF is no longer degraded, and the protein stabilizes and begins to build up in the cell (Figure) . Stable HIF then acts as a transcription factor that causes the upregulation of several genes involved in the hypoxia response. Many of these genes, such as vascular endothelial growth factor (VEGF), are responsible for angiogenesis as well as cellular growth and metabolism. HIF dysfunction has been implicated in many types of human tumors. It is thought that, in the adrenal gland, mutations of SDHB and SDHD cause tumor formation through the buildup of succinate. High levels of succinate interfere with the VHL-mediated degradation of HIF by preventing prolyl hydroxylases from hydroxylating HIF, which is a key step in the VHL process. Mutations of VHL, SDHB, and SDHD lead to abnormal HIF activation, causing overexpression of angiogenesis factors and tumor formation (Figure) . 14 The second set of related mutations cause abnormal expression of genes involved in RNA synthesis, protein production, and kinase signaling.
14 It remains unclear exactly how these mutations cause the abnormal gene expression profi les that lead to tumor formation. However, RET, NF1, and KIF1BBeta all participate in the molecular cascade that leads to apoptosis. Mutations of these genes are thought to decrease apoptosis, leading to abnormal cell growth. RET and NF1 have both been shown to activate the MAPK pathway of cellular signaling via abnormal RAS activation. Abnormal RAS protein signaling has been implicated in a wide variety of human tumors.
The recent improved understanding of the molecular pathways that cause malignant pheochromocytoma formation is leading to the development of new drug therapies. These designer drugs are targeted at disrupting the abnormal cell signaling that is created by these mutations. While none is currently in clinical use, many are now being studied in clinical trials.
I

-MIBG Radiation Therapy
MIBG is structurally similar to noradrenaline. This causes its uptake and concentration into chromaffi n cells, making it useful as an imaging tool for pheochromocytomas and paragangliomas of sympathetic origin. In 1984, investigators at the University of Michigan realized that this property of specifi c uptake by pheochromocytomas could make it a useful therapeutic tool as well. 15, 16 Ra- , known to be effective in treating thyroid cancer, was attached to the MIBG molecule to produce I 131 -MIBG, which at high enough doses could then be used as a semi-selective radiation therapy agent for malignant pheochromocytoma. The fact that it must be taken up specifi cally by the cells of the tumor is also one of its drawbacks. Some malignant pheochromocytomas do not take up MIBG, and in these tumors, I
131 -MIBG therapy is useless. External beam radiation therapy abolishes the ability of these tumors to take up MIBG, making this treatment ineffective in any tumor that has been irradiated. 17 Since 1984, many case reports have demonstrated the utility of I 131 -MIBG radiation therapy for treating symptomatic disease, and a few cases of complete responses have been published. A retrospective review of 116 patients showed a tumor response in 30%, a biochemical response in 45%, and symptomatic relief in 76%. 18 Another recent retrospective review of 19 patients showed an objective tumor response in 47%, a biochemical response rate of 67%, and temporary symptomatic relief in 89%. 19 That study also reported a hematologic complication rate in 26%. A phase II clinical trial of high-dose I 131 -MIBG therapy in 30 patients showed a 67% tumor response rate and a 75% 5-year survival rate. Because high-dose I 131 -MIBG therapy is myeloablative, stem cells from peripheral blood must be obtained before treatment. 20 I 131 -MIBG therapy is the most widely studied nonsurgical therapy for malignant pheochromocytoma and is considered the most useful treatment for patients whose tumors are not resectable. Many case reports have been published on the use of I 131 -MIBG therapy, with only a few large case series and one prospective controlled trial. [18] [19] [20] Consequently, evidence-based assumptions about the utility of this therapy are problematic. Clearly, I
131 -MIBG therapy is not curative, but some evidence suggests a high-dose regimen can result in sustained complete remission in a small number of patients. Its high side effect profi le at higher doses and low improvement in overall survival make it less than ideal, but it remains the best nonsurgical option to date.
Chemotherapy
Many different types of systemic chemotherapy for malignant pheochromocytoma have been tried, with varying degrees of success. One of the most diffi cult aspects of understanding the utility of chemotherapy for malignant pheochromocytoma is that few prospective trials have investigated different types of chemotherapy options ( Table 2) . [21] [22] [23] [24] [25] Instead, most knowledge about the effectiveness of chemotherapy is based on anecdotal evidence and single patient experiences. 26 In a 1988 study that remains one of the largest series published on chemotherapy for malignant pheochromocytoma, 14 patients from the National Institutes of Health (NIH) were treated in a trial of combined cyclophosphamide, vincristine, and dacarbazine (CVD therapy). 25 This regimen was chosen because of its high rate of success in treating neuroblastoma. Because neuroblastoma and pheochromocytoma are both neuroendocrine tumors, the thinking was that CVD therapy might be effective for pheochromocytoma. The NIH updated the study with an additional 4 patients in a 22-year follow-up analysis. 22 In the trial, 55% of the tumors had a positive response to the treatment by decreased size criteria and 72% of the tumors had a biochemical response. The median duration of the response was 20 months. The trial also showed that biochemical markers -24-hour urine catecholamines, metanephrines, and vanillylmandelic acid -are useful for determining tumor response, relapse, and progression. Based on this trial, which is the largest trial to date, CVD therapy resulted in no statistically signifi cant survival advantage. It remains useful for controlling symptoms of catecholamine excess in at least 50% of patients who have unresectable disease. Because 55% of tumors had a signifi cant reduction in size after treatment, CVD may be benefi cial in select cases as a neoadjuvant therapy to improve the chances of surgical resection in large tumors, but no study has addressed this specifi cally. 22 Patients being treated with CVD therapy need antihypertensive blockade beforehand because the therapy can cause a hypertensive crisis secondary to catecholamine release during treatment. Another combination chemotherapy regimen (cyclophosphamide, doxorubicin, and dacarbazine) showed a tumor response rate of 46%, 24 which was somewhat lower than that for CVD therapy. Other regimens that have been tested in smaller numbers of patients include (1) cisplatin and 5-fl uorouracil, (2) etoposide, carboplatin, vincristine, cyclophosphamide, and doxorubicin, (3) CVD with anthracycline, (4) cyclophosphamide and methotrexate, (5) temozolomide, and (6) streptozocin with varying combinations of other agents. 22, 27 Most of these regimens have been shown to be either ineffective or effective in so few patients that no evidence-based conclusions can be drawn about their utility for treating malignant pheochromocytoma.
In summary, CVD therapy is the most widely used systemic chemotherapy regimen for malignant pheochromocytoma. Its use is mostly reserved for patients with unresectable disease who are symptomatic from catecholamine excess and had no response to I 131 -MIBG therapy. However, because CVD therapy has no proven survival benefi t, it should not be routinely administered to all patients with metastatic disease. It may have some role as a neoadjuvant therapy. The tumor typically recurs once the chemotherapy regimen is stopped, and once the tumor recurs, it may become unresponsive to that same regimen. 22 Because any chemotherapy for malignant pheochromocytoma needs to be given long-term, it has to be considered on a case-by-case basis.
Radiation Therapy and Radiofrequency Ablation
Many case reports but few large patient series or controlled trials have been published on the use of radiation for malignant pheochromocytoma. A seminal review of the literature in 1978 concluded that radiation therapy is not useful as a primary mode of therapy and does not prevent local recurrence. 26 Its main benefi t is for controlling symptoms and pain associated with bone and lymph node metastasis. Since then, additional case reports have shown radiation therapy to be somewhat useful for bone metastasis, but generally, a malignant pheochromocytoma is thought to be a radiation-resistant tumor. 28 Cyberknife radiation therapy delivers external radiation in a focused manner, allowing for much higher doses to be given with fewer side effects to the surrounding normal tissue. 29 No studies have specifically investigated the use of cyberknife for a malignant pheochromocytoma, but cyberknife is a well-established method of treating bone metastasis of other tumor types, and it likely has a role in treating bone metastasis in malignant pheochromocytoma.
Little information is available on the use of radiofrequency ablation of metastatic pheochromocytoma lesions. 30 A recent case series of seven tumors describes successful ablation of the tumor tissue in all but one case, although follow-up data were not available to determine the response rate and possible recurrence of the tumors. 31 Data from adrenocortical carcinoma suggest that radiofrequency ablation of tumors within the adrenal gland is safe, but no data are available on the effi cacy of this procedure for pheochromocytomas. 32 More experience with radiofrequency ablation of malignant pheochromocytoma is needed to determine its usefulness in treating these cancers.
Experimental and Targeted Therapies
The discoveries of molecular pathways and genetic mutations that characterize malignant pheochromocytomas and paragangliomas have greatly enhanced the ability to design specifi c anticancer therapies. Most of these therapies have cytostatic properties in that they not only kill cancer cells, but also can interfere with the cytotoxic activity of other chemotherapeutic drugs. In addition, they can modulate the activity of key enzymes responsible for the specifi c signaling pathways capable of transforming benign pheochromocytomas and paragangliomas to their malignant counterparts. The cytostatic properties of these anticancer therapies are derived from the specifi c molecular targets found along the oncogenic signaling pathways that promote carcinogenesis and tumor growth. 27 Specifi c receptors and proteins have been discovered and refl ect the different genetic "clusters" that categorize the malignant transformation of these adrenal neoplasms. With the help of bioinformatics systems, high throughput genomics and proteomics have been instrumental in defi ning some of the mutations that subsequently lead to the development of several targeted therapies for the treatment of malignant pheochromocytomas and paragangliomas.
Therapeutic Targets
Heat Shock Protein 90 (Hsp90) -This multichaperone ATP-dependent complex is responsible for folding therapeutically relevant proteins, and it plays an important role in the stability and function of a host of oncoproteins (BCR-ABL, ERBB2, EGFR, CRAF, BRAF, AKT, MET, VEGFR, FLT3, AR, ER, HIF, and telomerase). 33 These oncoproteins are responsible for many molecular processes usually attributed to the malignant phenotype, including growth factor independence, resistance to antigrowth signals, cell replication, tumor invasion and metastases, angiogenesis, and lack of apoptosis. 34 Hsp90 may represent a potential therapeutic target as high levels of Hsp90 protein expression have been found in malignant compared to benign pheochromocytomas. 35 Because of the many oncogenic signaling pathways regulated by Hsp90, inhibitors of Hsp90 can target several oncogenic proteins in parallel. 34, 36 Currently, no known drug trials are using Hsp90 inhibitors specifi cally against malignant pheochromocytomas or paragangliomas.
mTOR Inhibitors -The PI3K/AKT/mTOR pathway is responsible for regulating cell growth and survival.
If this pathway becomes dysfunctional, mTOR becomes upregulated, leading to increased cell proliferation, angiogenesis, and evasion of apoptosis. 37 The mTOR inhibitor everolimus (RAD001) in combination with octreotide has been shown to be effective for low-and intermediategrade neuroendocrine tumors. Most patients experienced either a partial response or stable disease, with a minority experiencing tumor progression. 38 Along with this study, in vivo and in vitro experiments demonstrated a possible link between increased activity in the AKT pathway and the development of adrenal pheochromocytomas.
39-41 However, while case series have shown that everolimus is not effective in treating patients with malignant pheochromocytoma because all patients experienced disease progression, 42, 43 the above-mentioned patients had aggressive disease with distant metastases, which likely infl uenced the outcomes of the study. Further studies on the PI3K/AKT/mTOR pathway may still be needed to determine a more specifi c molecular target along its path.
HIF Inhibitors -HIF is a key regulator of the tumor environment and has spawned the research and development of several targeted therapies. 44 Some agents being investigated are PX-12 (1-methylpropyl 2-imidazolyl disulfi de) and PX-478 (S-2-amino-3-[4´-N,N,-bis (2-chloroethyl)amino]-phenyl propionic acid N-oxide dihydrochloride). HIF activity is decreased indirectly by PX-12 and is directly inhibited by PX-478. Although no data have been reported for malignant pheochromocytomas and paragangliomas, these agents have shown marked antitumor activity in various human tumor xenografts in mice. 45, 46 Studies are still required to determine the potential use of these new therapeutic targets.
Prolyl Hydroxylase Activators -Recent evidence has now indicated that activators of prolyl hydroxylase, such as R59949 and KRH102053, result in increased hydroxylation of HIF, which ultimately decreases the expression of proteins that regulate angiogenesis and those that resist apoptosis (Figure) . 47, 48 As our understanding of the association between the HIF pathway and the role of prolyl hydroxylases in pheochromocytomas continues to expand, it is likely to lead to the discovery of new antineoplastic agents.
ERBB2 (HER-2/neu) Inhibitors -ERBB2 is a receptor tyrosine kinase involved in cell growth and differentiation. When activated, ERBB2 leads to the synthesis of HIF, which subsequently leads to the overexpression of VEGF. 49 The presence of ERBB2 overexpression is associated with an increase in tumor metastasis and resistance to cancer treatment. 50 ERBB2 was signifi cantly overexpressed in malignant pheochromocytomas compared to benign or extra-adrenal pheochromocytomas. 51 Although ERBB2 may be overexpressed, this does not necessarily imply that it would serve as a useful therapeutic target, as seen by the HER-2/neu oncogene and the response of targeted therapies in breast cancer. 52 To date, there have been no published trials using ERBB2 (HER-2/neu) inhibitors for patients diagnosed with malignant pheochromocytomas. Clinical trials assessing the effi cacy of trastuzumab (Herceptin) may be on the horizon.
Specifi c Therapies
Thalidomide -Initially introduced in the 1950s as a sedative, thalidomide was quickly removed from the market when its teratogenic effects became known. At the turn of this century, thalidomide, in combination with dexamethasone, gained popularity when it was shown to increase survival in patients diagnosed with multiple myeloma. 53 Thalidomide is an antiangiogenic agent, specifi cally targeting VEGF and basic fi broblast growth factor (bFGF). 54 Several phase III trials are studying the effects of thalidomide in metastatic renal cell cancer, multiple myeloma, and non-small cell lung cancer. 55 To date, only one phase II trial has been conducted to de- termine the effi cacy of thalidomide in combination with temozolomide, a cytotoxic chemotherapeutic agent, as an alternative to streptozocin-based therapy in neuroendocrine tumors. 54 In the pheochromocytoma group, which included 3 patients, a partial radiologic response to the therapy occurred in 1 patient. Due to the limited number of cases, it is impossible to draw any conclusions about the effi cacy of thalidomide in pheochromocytoma patients. However, the combination of thalidomide and temozolomide may offer some benefi t to pheochromocytoma patients in addition to patients with carcinoid and/or pancreatic neuroendocrine tumors.
54
Imatinib Mesylate -This tyrosine kinase inhibitor specifi cally inhibits the protein tyrosine kinase activity of the BCL-ABL, c-KIT, and PDGF-R enzymes. 56 Imatinib, as a targeted therapy against the BCL-ABL gene and the tyrosine kinase protein c-KIT, became important as an effective treatment for hematologic malignancies (eg, chronic myelogenous leukemia) as well as solid tumors (eg, gastrointestinal stromal tumors). Several studies were designed to determine whether other solid endocrine malignancies expressed either PDGF-R or c-KIT. 56 ,57 Yet, the data for patients with malignant pheochromocytomas (n = 2) indicated progression of disease. Interestingly, the immunohistochemical profi les of these tumors (PDGF-R+ and c-KIT+; PDGF-R+ and c-KIT-) made no difference in the tumors' response to imatinib.
56
Sunitinib -Sunitinib is a receptor tyrosine kinase inhibitor that acts on several targets (VEGF, PDGF, c-KIT) and demonstrates antiangiogenic and antitumor activity. 58 The mechanism by which sunitinib acts on malignant pheochromocytomas and paragangliomas is associated with the mutation of the VHL gene. The VHL gene, as previously mentioned, leads to the activation of HIF and 
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Interventional; treatment upregulates both VEGF and PDGF. Sunitinib can inhibit both the VEGF and PDGF receptors, as was previously shown in renal cell malignancies. 59 Case studies have reported partial or near-complete tumor regression after treatment with sunitinib by measuring tumor size, performance status, patient symptoms, and reduction of biochemical tumor marker (normetanepherines and chromogranin A) levels.
58, 60 The preliminary results of the effectiveness of sunitinib as a molecular-targeted therapy for malignant pheochromocytomas and paragangliomas are promising. Phase II trials are currently underway (Table 3) . 38, 43, [45] [46] [47] [48] 54, 56, 58, 60, 61 Clinical Trials Several phase I and II clinical trials are currently recruiting patients who have been diagnosed with either malignant or refractory pheochromocytomas and paragangliomas or with other metastatic neuroendocrine tumors expressing somatostatin receptors. The spectrum of trials ranges from the discovery of novel diagnostic assays for pheochromocytomas/paragangliomas to novel targeted therapeutic agents and newly radiolabeled somatostatin analogs for the treatment of these malignant tumors. Table 4 lists the clinical trials that are recruiting new patients. If successful, the new agents being studied in these trials might improve the treatment of malignant pheochromocytomas and paragangliomas.
Conclusions
No effective cure currently exists for patients diagnosed with malignant pheochromocytomas and paragangliomas. Until now, no histopathologic markers could be used to distinguish between a benign and malignant pheochromocytoma. However, over the past several decades, advances in bioinformatics and molecular biology have provided the impetus for the discovery of new diagnostic and prognostic tests, better imaging techniques, and improvements in chemotherapy, radiation therapy, and therapeutic regimens that use nuclear medicine technology. With the help of genomic and proteomic studies, novel tumor markers are currently being discovered and the paths of malignant transformation are now better defi ned. Despite these improvements, limitations still exist. Malignant pheochromocytomas and paragangliomas are rare cancers, and ambiguity persists for physicians and surgeons in terms of the available treatment strategies. Although several studies show promising results, development of an evidence-based approach is essential. The future of research for these tumors lies in the development of patient registries, international tissue bank programs, and collaborative prospective clinical trials for the treatment of these rare malignancies.
